Trial Outcomes & Findings for The Role of Matrix Metalloproteinase 2 and 9 Enzymes in Developing Chronic Thromboembolic Pulmonary Hypertension (NCT NCT04773028)
NCT ID: NCT04773028
Last Updated: 2021-08-10
Results Overview
Measurement the concentration of matrix metalloproteinase 2 and 9 enzymes by elisa and western blot techniques.
Recruitment status
COMPLETED
Target enrollment
48 participants
Primary outcome timeframe
1 year
Results posted on
2021-08-10
Participant Flow
Participant milestones
| Measure |
PATİENT GROUP(GROUP 1)
This group is the group that underwent pulmonary thromboendarterectomy due to chronic thromboembolic pulmonary hypertension.Sample was taken from the material extracted from this group during operation.
matrix metalloproteinase enzymes 2 and 9: concentration of matrix metalloproteinase 2 and 9 enzymes
|
CONTROL GROUP(GROUP 2)
This group is the group that underwent lobectomy or pneumonectomy for another reason that the pulmonary artery is not affected. Patients operated for a reason other than chronic thromboembolic pulmonary hypertension and samples were taken from the intact pulmonary artery of the removed lung.
matrix metalloproteinase enzymes 2 and 9: concentration of matrix metalloproteinase 2 and 9 enzymes
|
|---|---|---|
|
Overall Study
STARTED
|
24
|
24
|
|
Overall Study
COMPLETED
|
24
|
24
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
The Role of Matrix Metalloproteinase 2 and 9 Enzymes in Developing Chronic Thromboembolic Pulmonary Hypertension
Baseline characteristics by cohort
| Measure |
PATİENT GROUP(GROUP 1)
n=24 Participants
This group is the group that underwent pulmonary thromboendarterectomy due to chronic thromboembolic pulmonary hypertension.Sample was taken from the material extracted from this group during operation.
matrix metalloproteinase enzymes 2 and 9: concentration of matrix metalloproteinase 2 and 9 enzymes
|
CONTROL GROUP(GROUP 2)
n=24 Participants
This group is the group that underwent lobectomy or pneumonectomy for another reason that the pulmonary artery is not affected. Patients operated for a reason other than chronic thromboembolic pulmonary hypertension and samples were taken from the intact pulmonary artery of the removed lung.
matrix metalloproteinase enzymes 2 and 9: concentration of matrix metalloproteinase 2 and 9 enzymes
|
Total
n=48 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
age
|
49.04 years
STANDARD_DEVIATION 10.8 • n=5 Participants
|
57.8 years
STANDARD_DEVIATION 15.4 • n=7 Participants
|
53.42 years
STANDARD_DEVIATION 12.9 • n=5 Participants
|
|
Sex: Female, Male
Female
|
11 Participants
n=5 Participants
|
8 Participants
n=7 Participants
|
19 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
13 Participants
n=5 Participants
|
16 Participants
n=7 Participants
|
29 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
24 Participants
n=5 Participants
|
24 Participants
n=7 Participants
|
48 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Region of Enrollment
Turkey
|
24 participants
n=5 Participants
|
24 participants
n=7 Participants
|
48 participants
n=5 Participants
|
|
height
|
166.6 cm
STANDARD_DEVIATION 10.2 • n=5 Participants
|
166.7 cm
STANDARD_DEVIATION 7.6 • n=7 Participants
|
166.65 cm
STANDARD_DEVIATION 8.9 • n=5 Participants
|
|
Weight
|
85.4 kg
STANDARD_DEVIATION 14.2 • n=5 Participants
|
73.5 kg
STANDARD_DEVIATION 13.9 • n=7 Participants
|
79.45 kg
STANDARD_DEVIATION 14.05 • n=5 Participants
|
PRIMARY outcome
Timeframe: 1 yearMeasurement the concentration of matrix metalloproteinase 2 and 9 enzymes by elisa and western blot techniques.
Outcome measures
| Measure |
PATİENT GROUP(GROUP 1)
n=24 Participants
This group is the group that underwent pulmonary thromboendarterectomy due to chronic thromboembolic pulmonary hypertension.Sample was taken from the material extracted from this group during operation.
matrix metalloproteinase enzymes 2 and 9: concentration of matrix metalloproteinase 2 and 9 enzymes
|
CONTROL GROUP(GROUP 2)
n=24 Participants
This group is the group that underwent lobectomy or pneumonectomy for another reason that the pulmonary artery is not affected. Patients operated for a reason other than chronic thromboembolic pulmonary hypertension and samples were taken from the intact pulmonary artery of the removed lung.
matrix metalloproteinase enzymes 2 and 9: concentration of matrix metalloproteinase 2 and 9 enzymes
|
|---|---|---|
|
Concentration of Matrix Metalloproteinase 2 and 9 Enzymes
PRO MMP 2
|
89289.89 ng/ml
Standard Deviation 84639.26
|
86548.72 ng/ml
Standard Deviation 45312.33
|
|
Concentration of Matrix Metalloproteinase 2 and 9 Enzymes
ACTİVE MMP 2
|
205707.83 ng/ml
Standard Deviation 388888.77
|
152911.57 ng/ml
Standard Deviation 44400.16
|
|
Concentration of Matrix Metalloproteinase 2 and 9 Enzymes
MMP 9
|
88975.83 ng/ml
Standard Deviation 94129.68
|
182029.76 ng/ml
Standard Deviation 140527.87
|
Adverse Events
PATİENT GROUP(GROUP 1)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
CONTROL GROUP(GROUP 2)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr.Ahmet Zengin
Kartal Kosuyolu Hihg Speciality Training and Research Hospital
Phone: +905365022173
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place